Buradasınız

Anasayfa » Content

Kronik Böbrek Hastalığı Evre 3-5 Hastalarda Serum CXCL-16 Düzeylerinin Önemi

The Importance of Serum CXCL-16 Levels in Patients with Grade III-V Chronic Kidney Disease

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 2014
DOI: 
10.5262/tndt.2014.1003.10

Key Words:

Keywords (Original Language):

Author NameUniversity of Author
Abstract (2. Language): 
OBJECTIVE: A number of studies report CXCL-16 as a new chemokine that mediates the collection of leukocytes and adhesion of macrophages to coronary artery smooth muscle cells, and stimulates atherosclerosis. However, there is a limited number of studies evaluating the levels of CXCL-16 in patients with Chronic Kidney Disease (CKD). We aimed to determine the serum level of CXCL-16 in patients with CKD and to clarify the relationship between CXCL-16 and hsCRP and glomerular filtration. MATERIAL and METHODS: Two hundred and twenty two patients with CKD were included in the study. The patients were divided into 3 groups according to the glomerular filtration rate (GFR) in accordance with the K/DOQI guideline. Patients with primary glomerulonephritis or tubulointerstitial nephritis, heart failure, or hepatic disease, patients who used immunosuppressive or cytotoxic drugs and renin-angiotensin system blockers were excluded from the study. RESULTS: There was a positive correlation between the grade of renal failure and CXCL-16 levels and a negative correlation between the GFR and CXCL-16 levels ( p<0.001).There was a positive correlation between CXCL-16 and hsCRP ( p <0.001). Decreased GFR, increased PTH and hsCRP levels, and the presence of DM and HT were associated with serum CXCL-16 elevation on multiple regression analysis. CONCLUSION: The results indicated that decreased GFR levels were associated with increased hsCRP and CXCL-16 levels in chronic kidney disease.
Bookmark/Search this post with
Abstract (Original Language): 
AMAÇ: Yeni bir kemokin olarak kemokin ligand-16 (CXCL-16) lökositlerin toplanmasına, makrofajların koroner arter düz kas hücrelerine adezyonuna aracılık ettiği ve aterosklerozu hızlandırdığı birçok çalışmayla gösterilmiştir. Kronik böbrek hastalığı grubunda CXCL-16 düzeyleri ile ilgili fazla çalışma yoktur. Amacımız, kronik böbrek hastalığında serum CXCL-16 düzeyleri ile hsCRP, glomerüler filtrasyon değeri arasındaki ilişkiyi değerlendirmektir. GEREÇ ve YÖNTEMLER: Kronik böbrek hastalıklı 222 hasta çalışmaya alınmıştır. Hastalar K/ DOQI kılavuzunda belirlenen glomerüler filtrasyon değerine (GFD) göre 3 gruba ayrılmıştır. Çalışmaya alınan tüm kişilerden venöz kan örneği alınmış ve detaylı metabolik panele ilaveten CXCL-16 ve hsCRP için de kan örnekleri alınmıştır. Aktif glomerülonefrit veya tubulointerstisiyel nefritli hastalar, kalp yetmezliği ve hepatik hastalığı nedeniyle takip edilen hastalar, immünosupresif veya sitotoksik ilaç kullananlar ile renin anjiyotensin sistemini bloke eden ilaç kullanan hastalar çalışmaya alınmamıştır. BULGULAR: Kronik böbrek hastalığında progresyon oldukça yani hasta evre 3’ten evre 5’e kadar ilerledikçe serum CXCL-16 değerleri artmış, GFD ile CXCL-16 düzeyleri arasında negatif bir korelâsyon saptanmıştır (r=-0,457, p<0,001). Kronik böbrek hastalığı ilerledikçe endotel fonksiyonu da giderek bozulmuş ve bunun bir göstergesi olarak hsCRP değerleri de artmıştır ( p<0,001). CXCL-16 ile hsCRP arasında da pozitif bir korelasyon saptanmıştır (r=0,359 p<0,001). Yapılan çoklu regresyon analizinde serum CXCL-16 artışı ile GFD azalma, DM ve HT varlığı, yüksek PTH, hsCRP ve PTH değerleri ilişkili bulunmuştur.SONUÇ: Sonuçlar kronik böbrek hastalığında GFD azalmasına hsCRP artışının yanında serum CXCL-16 artışının da eşlik ettiğini göstermiştir. Framingham risk faktörleri ile ilişkili olan bu kemokinin böbrek hastalığının progresyonunda ve komplikasyonların gelişiminde önemli bir rol oynadığı düşünülmektedir.
FULL TEXT (PDF): 
PDF icon arastirmax-kronik-bobrek-hastaligi-evre-3-5-hastalarda-serum-cxcl-16-duzeylerinin-onemi.pdf
  • 3
234
239
  • Turkish

REFERENCES

References: 

1. National Kidney Foundation. K/DOQI kidney disease outcome
quality initiative. Am J Kidney Dis 2002;39(Suppl 1):S1-S266
2. Süleymanlar G, Utaş C, Arinsoy T, Ateş K, Altun B, Altiparmak MR,
Ecder T, Yilmaz ME, Çamsari T, Başçi A, Odabas AR, Serdengeçti
K: A population-based survey of chronic renal disease in Turkey-the
CREDIT study. Nephrol Dial Transplant 2011; 26(6); 1862-1871
3. Hostetter TH: Chronic kidney disease predicts cardiovascular
disease. N Engl J Med 2004; 351: 1344-1346
4. McClellan WM, Newsome BB, McClure LA, Cushman M, Howard
G, Audhya P, Abramson JL, Warnock DG: Chronic kidney disease
is often unrecognized among patients with coronary heart disease:
The REGARDS Cohort Study. Am J Nephrol 2009; 29: 10-17
5. Muntner P, He J, Astor BC, Folsom AR, Coresh J: Traditional and
nontraditional risk factors predict coronary heart disease in chronic
kidney disease: Results from the atherosclerosis risk in communities
study. J Am Soc Nephrol 2005; 16: 529-538
6. Himmelfarb J, McMonagle E, Freedman S, Klenzak J, McMenamin
E, Le P, Lara B, Pupim T, Ikizler A; The PICARD Group: Oxidative
stress is increased in critically ill patients with acute renal failure. J
Am Soc Nephrol 2004; 15: 2449-2456
7. Kao MP, Ang DS, Pall A, Struthers AD: Oxidative stress in renal
dysfunction: Mechanisms, clinical sequelae and therapeutic options.
J Hum Hypertens 2010; 24: 1-8
8. Kovesdy CP, Kalantar-Zadeh K: Review article: Biomarkers of
clinical outcomes in advanced chronic kidney disease. Nephrology
(Carlton) 2009; 14(4): 408-415
9. Massy ZA, Stenvinkel P, Drueke TB: The role of oxidative stress in
chronic kidney disease. Semin Dial 2009; 22: 405-408
10. Bosmans JL, Holvoet P, Dauwe SE, Ysebaert DK, Chapelle T,
Jürgens A, Kovacic V, Van Marck EA, De Broe ME, Verpooten GA:
Oxidative modification of low-density lipoproteins and the outcome
of renal allografts at 2 years. Kidney Int 2001; 59: 2346-2356
11. Meier P, Spertini F, Blanc E, Burnier M: Oxidized low-density
lipoproteins activate CD4+ T cell apoptosis in patients with endstage
renal disease through Fas engagement. J Am Soc Nephrol
2007; 18: 331-342
12. Shimaoka T, Kume N, Minami M, Hayashida K, Kataoka H, Kita
T, Yonehara S: Molecular cloning of a novel scavenger receptor for
oxidized low density lipoprotein, SR-PSOX, on macrophages. J
Biol Chem 2000; 275:40663-40666
239
Türk Nefroloji Diyaliz ve Transplantasyon Dergisi
Turkish Nephrology, Dialysis and Transplantation Journal
Ünal HU et al : The Importance of Serum CXCL-16 Levels in Patients
with Grade III-V Chronic Kidney Disease
Turk Neph Dial Transpl 2014; 23 (3): 234-239
13. Wilbanks A, Zondlo SC, Murphy K, Mak S, Soler D, Langdon P,
Andrew DP, Wu L, Briskin M: Expression cloning of the STRL33/
BONZO/TYMSTR ligand reveals elements of CC, CXC, and CX3C
chemokines. J Immunol 2001; 166: 5145-5154
14. Matloubian M, David A, Engel S, Ryan JE, Cyster JG: A
transmembrane CXC chemokine is a ligand for HIV-coreceptor
Bonzo. Nat Immunol 2000; 1(4): 298-304
15. Gough PJ, Garton KJ, Wille PT, Rychlewski M, Dempsey PJ, Raines
EW: A disintegrin and metalloproteinase 10-mediated cleavage and
shedding regulates the cell surface expression of CXC chemokine
ligand. J Immunol 2004; (172): 3678-3685
16. Abel S, Hundhausen C, Mentlein R, Schulte A, Berkhout TA,
Broadway N, Hartmann D, Sedlacek R, Dietrich S, Muetze
B, Schuster B, Kallen KJ, Saftig P, Rose JS, Ludwig A: The
transmembrane CXC chemokine ligand 16 is induced by IFN and
TNF and shed by the activity of the disintegrin-like metalloproteinase
ADAM10. J Immunol 2004; 172: 6362-6372
17. Kim CH, Kunkel EJ, Boisvert J, Johnston B, Campbell JJ, Genovese
MC, Greenberg HB, Butcher EC: Bonzo/CXCR6 expression defines
type polarized T-cell subsets with extralymphoid tissue homing
potential. J Clin Invest 2001; 107(5): 595-601
18. Gürsel M, Gürsel I, Mostowski HS, Klinman DM: CXCL16
influences the nature and specificity of CpG-induced immune
activation. J Immunol 2006; 177(3); 1575-1580
19. Schramme A, Abdel Bakky MS, Gutwein P, Obermüller N, Baer PC,
Hauser IA, Ludwig A, Gauer S, Schäfer L, Sobkowiak E, Altevogt
P, Koziolek M, Kiss E, Gröne HJ, Tikkanen R, Goren I, Radeke H,
Pfeilschifter J: Characterization of CXCL-16 and ADAM10 in the
normal and transplanted kidney. Kidney Int 2008; 74: 328-338
20. Gutwein P, Abdel-Bakky MS, Schramme A, Doberstein K, Kämpfer-
Kolb N, Amann K, Hauser IA, Obermüller N, Bartel C, Abdel-
Aziz AA, El Sayed el SM, Pfeilschifter J: CXCL16 is expressed in
podocytes and acts as a scavenger receptor for oxidized low-density
lipoprotein. Am J Pathol 2009; 174(6): 2061-2072
21. Gough PJ, Garton KJ, Wille PT, Rychlewski M, Dempsey PJ, Raines
EW: A disintegrin and metalloproteinase 10-mediated cleavage and
shedding regulates the cell surface expression of CXC chemokine
ligand 16. J Immunol 2004; 172: 3678-3685
22. Lin Z, Gong Q, Zhou Z, Zhang W, Liao S, Liu Y, Yan X, Pan X, Lin
S, Li X: Increased plasma CXCL-16 levels in patients with chronic
kidney diseases. Eur J Clin Invest 2011; 41 (8): 836-845
23. Yılmaz Mİ, Sağlam M, Caglar K, Çakır E, Özgürtaş T, Sönmez
A, Eyileten T, Yenicesu M, Açıkel C, Oğuz Y, Özcan O, Bozlar
U, Erbil K, Aslan İ, Vural A: Endothelial functions improve with
decrease in asymmetric dimethylarginine (ADMA) levels after
renal transplantation. Transplantation 2005; 80(12): 1660-1666
24. Yılmaz Mİ, Sağlam M, Caglar K, Cakır E, Sonmez A, Özgürtaş T,
Aydın A, Eyileten T, Ozcan Ö, Açıkel C, Taşar M, Gençtoy G, Erbil
K, Vural A, Zoccali C: The determinants of endothelial dysfunction
in CKD: Oxidative stress and asymmetric dimethylarginine. Am J
Kidney Dis 2006; 47(1): 42-50
25. Wilbanks A, Zondlo SC, Murphy K, Mak S, Soler D, Langdon P,
Andrew DP, Wu L, Briskin M: Expression cloning of the STRL33/
BONZO/TYMSTR ligand reveals elements of CC, CXC, and
CX3C chemokines. J Immunol 2001; 166: 5145-5154
26. Lehrke M, Millington SC, Lefterova M, Cumaranatunge RG,
Szapary P, Wilensky R, Rader DJ, Lazar MA, Reilly MP: CXCL-
16 is a marker of inflammation, atherosclerosis, and acute coronary
syndromes in humans. J Am Coll Cardiol 2007; 49(4): 442-449
27. Barlic J, Zhu W, Murphy PM: Atherogenic lipids induce highdensity
lipoprotein uptake and cholesterol efflux in human
macrophages by up-regulating transmembrane chemokine CXCL16
without engaging CXCL16-dependent cell adhesion. J Immunol
2009; 182(12): 7928-7936
28. Tabata S, Kadowaki N, Kitawaki T, Shimaoka T, Yonehara T, Yoshie
O, Uchiyama T: Distribution and kinetics of SR-PSOX/CXCL-16
and CXCR6 expression on human dendritic cell subsets and CD4 T
cells. J Leukoc Biol 2005; 77(5): 777-786
29. Minami M, Kume N, Shimaoka T, Kataoka H, Hayashida K,
Akiyama Y, Nagata I, Ando K, Nobuyoshi M, Hanyuu M, Komeda
M, Yonehara S, Kita T: Expression of SR-PSOX, a novel cellsurface
scavenger receptor for phosphatidylserine and oxidized
LDL in human atherosclerotic lesions. Arterioscler Thromb Vasc
Biol 2001; 21: 1796-1800
30. Dong H, Toyoda N, Yoneyama H, Kurachi M, Kasahara T, Kobayashi
Y, Inadera H, Hashimoto S, Matsushima K: Gene expression profile
analysis of the mouse liver during bacteria-induced fulminant
hepatitis by a cDNA microarray system. Biochem Biophys Res
Commun 2002; 298: 675-686
31. Wågsater D, Hugander A, Dimberg J: Expression of CXCL-16 in
human rectal cancer. Int J Mol Med 2004; 14: 65-69
32. Garcia GE, Truong LD, Li P, Zhang P, Johnson RJ, Wilson CB, Feng
L: Inhibition of CXCL16 attenuates inflammatory and progressive
phases of anti-glomerular basement membrane antibody-associated
glomerulonephritis. Am J Pathol 2007; 170: 1485-1496
33. Gutwein P, Abdel-Bakky MS, Schramme A, Doberstein K, Kämpfer-
Kolb N, Amann K, Hauser IA, Obermüller N, Bartel C, Abdel-
Aziz AA, El Sayed el SM, Pfeilschifter J: CXCL16 is expressed in
podocytes and acts as a scavenger receptor for oxidized low-density
lipoprotein. Am J Pathol 2009; 174: 2061-2072
34. Sakai N, Wada T, Yokoyama H, Lipp M, Ueha S, Matsushima K,
Kaneko S: Secondary lymphoid tissue chemokine (SLC/CCL21)/
CCR7 signaling regulates fibrocytes in renal fibrosis. Proc Natl
Acad Sci U S A 2006; 103(38): 14098-14103
35. Chen G, Lin SC, Chen J, He L, Dong F, Xu J, Han S, Du J, Entman
ML, Wang Y: CXCL16 recruits bone marrow-derived fibroblast
precursors in renal fibrosis. J Am Soc Nephrol 2011; 22: 1876-1886

Thank you for copying data from http://www.arastirmax.com